Base de dados : MEDLINE
Pesquisa : A15.382.216 [Categoria DeCS]
Referências encontradas : 57900 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 5790 ir para página                         

  1 / 57900 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29480842
[Au] Autor:Chang CC; Cho SF; Chuang YW; Lin CY; Huang YF; Tyan YC
[Ad] Endereço:Department of Nuclear Medicine, Kaohsiung Medical University Hospital.
[Ti] Título:Prognostic significance of retention index of bone marrow on dual-phase 18F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with diffuse large B-cell lymphoma.
[So] Source:Medicine (Baltimore);97(2):e9513, 2018 Jan.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The purpose of this study was to determine the prognostic significance of F-18 fluorodeoxyglucose (FDG) uptake on a dual-phase positron emission tomography/computed tomography (PET/CT), focusing on the increment in maximal standardized uptake value (SUVinc) of tumor and bone marrow (BM) between initial and delayed phase images and retention index (RI) of tumor and BM, in patients with diffuse large B-cell lymphoma (DLBCL).From September 2009 to January 2013, 70 patients (37 males and 33 females, aged 60.6 ±â€Š17.5 years) with DLBCL who had undergone dual-phase FDG PET/CT scans for pretreatment staging were enrolled. The patients subsequently received combination chemotherapy with rituximab. The dual-phase SUV, including SUVinc of tumor (SUVinc-t), RI of tumor (RI-t), SUVinc of BM, and RI of BM were measured. The clinical observation period was from September 2009 to December 2014. Both univariate and multivariate analyses were then used to assess the prognostic significance of SUVinc, RI, international prognostic index (IPI), gender, age, clinical stage, and laboratory tests.The median follow-up time was 35.5 months. The 3-year overall survival (OS) for patients with low/high SUVinc-t (cut-off 2.0) and for patients with low/high RI-t (cut-off 20) were 87.5%/ 62.1% (P = .08) and 83.3%/ 62.7% (P = .14), respectively. The 3-year OS for patients with SUVinc-i < 0.35 and for those with SUVinc-i ≥ 0.35 were 73.2% and 53.3%, respectively (P = .10). The 3-year OS for patients with RI-i < 45 and for those with RI-i ≥ 45 were 72.7% and 37.5%, respectively (P = .02). Subsequently, the Cox multivariate forward proportional hazards model revealed that a higher RI-i (hazard ratio: 4.49; 95% confidence interval: 1.64-12.32; P = .0035) and IPI were independent prognostic factors affecting OS.For patients with DLBCL, an elevated RI-i (≥45) was a predictor for shorter OS, independent of IPI score. It added to the value of pretreatment dual-phase FDG PET/CT scans.
[Mh] Termos MeSH primário: Medula Óssea/diagnóstico por imagem
Fluordesoxiglucose F18
Linfoma Difuso de Grandes Células B/diagnóstico por imagem
Tomografia Computadorizada com Tomografia por Emissão de Pósitrons
Compostos Radiofarmacêuticos
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Antineoplásicos Imunológicos/uso terapêutico
Medula Óssea/efeitos dos fármacos
Medula Óssea/metabolismo
Feminino
Seguimentos
Seres Humanos
Linfoma Difuso de Grandes Células B/tratamento farmacológico
Linfoma Difuso de Grandes Células B/metabolismo
Masculino
Meia-Idade
Análise Multivariada
Prognóstico
Estudos Retrospectivos
Rituximab/uso terapêutico
Análise de Sobrevida
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antineoplastic Agents, Immunological); 0 (Radiopharmaceuticals); 0Z5B2CJX4D (Fluorodeoxyglucose F18); 4F4X42SYQ6 (Rituximab)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180305
[Lr] Data última revisão:
180305
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180227
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009513


  2 / 57900 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29327472
[Au] Autor:He Y; Xu LL; Feng FE; Wang QM; Zhu XL; Wang CC; Zhang JM; Fu HX; Xu LP; Liu KY; Huang XJ; Zhang XH
[Ad] Endereço:Peking University People's Hospital, Peking University Institute of Haematology, Beijing, China.
[Ti] Título:Mesenchymal stem cell deficiency influences megakaryocytopoiesis through the TNFAIP3/NF-κB/SMAD pathway in patients with immune thrombocytopenia.
[So] Source:Br J Haematol;180(3):395-411, 2018 02.
[Is] ISSN:1365-2141
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Immune thrombocytopenia (ITP) is an autoimmune disease. Mesenchymal stem cells (MSCs) play important roles in the physiology and homeostasis of the haematopoietic system, including supporting megakaryocytic differentiation from CD34 haematopoietic progenitor cells. Tumour necrosis factor alpha-induced protein 3 (TNFAIP3, also termed A20) plays a key role in terminating NF-κB signalling. Human genetic studies showed that the polymorphisms of the TNFAIP3 gene may contribute to ITP susceptibility. In this study, we showed a significant decrease in TNFAIP3 and increase in NF-κB/SMAD7 in ITP-MSCs. In co-cultures with CD34 cells, NF-κB was overexpressed in MSCs from healthy controls (HC-MSCs) after transfection with NFKBIA (IκB)-specific short hairpin (sh)RNAs, resulting in MSC deficiency and a reduction in megakaryocytic differentiation and thrombopoiesis. Knockdown of TNFAIP3 expression using TNFAIP3-specific shRNAs in HC-MSCs affected megakaryocytopoiesis. However, IKBKB knockdown corrected megakaryocytopoiesis inhibition in the ITP-MSCs by decreasing NF-κB expression. Amplified TNFAIP3 expression in ITP-MSCs by TNFAIP3 cDNA can facilitate megakaryocyte differentiation. shRNA-mediated knockdown of SMAD7 expression rescued the impaired MSC function in ITP patients. Therefore, we demonstrate that a pathological reduction in TNFAIP3 levels induced NF-κB/SMAD7 pathway activation, causing a deficiency in MSCs in ITP patients. The ability of ITP-MSCs to support megakaryocytic differentiation and thrombopoiesis of CD34 cells was impaired.
[Mh] Termos MeSH primário: Células Mesenquimais Estromais/metabolismo
NF-kappa B/metabolismo
Púrpura Trombocitopênica Idiopática/etiologia
Púrpura Trombocitopênica Idiopática/metabolismo
Transdução de Sinais
Proteínas Smad/metabolismo
Trombopoese
Proteína 3 Induzida por Fator de Necrose Tumoral alfa/metabolismo
[Mh] Termos MeSH secundário: Biomarcadores
Medula Óssea/patologia
Estudos de Casos e Controles
Diferenciação Celular
Ensaio de Unidades Formadoras de Colônias
Citocinas/biossíntese
Expressão Gênica
Seres Humanos
Imunofenotipagem
Células Mesenquimais Estromais/efeitos dos fármacos
Células Mesenquimais Estromais/patologia
Modelos Biológicos
NF-kappa B/genética
Púrpura Trombocitopênica Idiopática/diagnóstico
Púrpura Trombocitopênica Idiopática/tratamento farmacológico
Transdução de Sinais/efeitos dos fármacos
Proteínas Smad/genética
Trombopoese/efeitos dos fármacos
Trombopoese/genética
Fator de Crescimento Transformador beta/metabolismo
Tretinoína/farmacologia
Proteína 3 Induzida por Fator de Necrose Tumoral alfa/genética
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Biomarkers); 0 (Cytokines); 0 (NF-kappa B); 0 (Smad Proteins); 0 (Transforming Growth Factor beta); 5688UTC01R (Tretinoin); EC 3.4.19.12 (TNFAIP3 protein, human); EC 3.4.19.12 (Tumor Necrosis Factor alpha-Induced Protein 3)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180222
[Lr] Data última revisão:
180222
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180113
[St] Status:MEDLINE
[do] DOI:10.1111/bjh.15034


  3 / 57900 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29325312
[Au] Autor:Wang WJ; Sun YQ; Tang FF; Han TT; Mo XD; Wang JZ; Zhang XH; Huang XJ; Xu LP
[Ad] Endereço:Peking University People's Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing 100044, China.
[Ti] Título:[Outcomes of alternative donor allogeneic hematopoietic stem cell transplantation for Fanconi anemia: a five cases report].
[So] Source:Zhonghua Nei Ke Za Zhi;57(1):54-56, 2018 Jan 01.
[Is] ISSN:0578-1426
[Cp] País de publicação:China
[La] Idioma:chi
[Ab] Resumo:Five patients with Fanconi anemia who received hematopoietic cell transplantation were retrospectively analyzed. The conditioning regimens included fludarabine, cyclophosphamide and anti-thymocyte globulin. Two patients received both bone marrow and peripheral blood stem cells as the source of stem cell grafts from haploidentical matched related donors, while the others received peripheral blood stem cells from unrelated donors. All patients tolerated well and reached hematopoietic reconstitution. One patient died of intracranial infection. During follow-up, 4 patients survived independent of transfusion with full donor chimerism.
[Mh] Termos MeSH primário: Anemia de Fanconi/terapia
Doença Enxerto-Hospedeiro/prevenção & controle
Transplante de Células-Tronco Hematopoéticas
Condicionamento Pré-Transplante
[Mh] Termos MeSH secundário: Soro Antilinfocitário/administração & dosagem
Soro Antilinfocitário/uso terapêutico
Medula Óssea
Ciclofosfamida/administração & dosagem
Ciclofosfamida/uso terapêutico
Seres Humanos
Estudos Retrospectivos
Resultado do Tratamento
Doadores não Relacionados
Vidarabina/análogos & derivados
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antilymphocyte Serum); 8N3DW7272P (Cyclophosphamide); FA2DM6879K (Vidarabine); P2K93U8740 (fludarabine)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180222
[Lr] Data última revisão:
180222
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180112
[St] Status:MEDLINE
[do] DOI:10.3760/cma.j.issn.0578-1426.2018.01.010


  4 / 57900 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29265181
[Au] Autor:Horai M; Satoh S; Matsuo M; Iwanaga M; Horio K; Jo T; Takasaki Y; Kawaguchi Y; Tsushima H; Yoshida S; Taguchi M; Itonaga H; Sawayama Y; Taguchi J; Imaizumi Y; Hata T; Moriuchi Y; Haase D; Yoshiura KI; Miyazaki Y
[Ad] Endereço:Department of Haematology, Atomic Bomb Disease and Hibakusha Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
[Ti] Título:Chromosomal analysis of myelodysplastic syndromes among atomic bomb survivors in Nagasaki.
[So] Source:Br J Haematol;180(3):381-390, 2018 02.
[Is] ISSN:1365-2141
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:The myelodysplastic syndromes (MDS) are clonal haematopoietic disorders that develop de novo and also secondary to chemotherapy and/or radiation therapy. We previously demonstrated that the risk of MDS is increased among atomic bomb survivors with significant correlation to radiation dose; however, the clinical characteristics of these survivors have not been well analysed. In this study, we investigated chromosomal abnormalities of MDS among survivors. The frequency of abnormal karyotypes was significantly higher, with more very poor risk karyotypes, according to the revised International Prognostic Scoring System, among those exposed close to the hypocentre compared with unexposed cases. However, abnormal karyotype frequency did not reflect the prognosis of exposed cases with respect to distance from the hypocentre. In addition, there was no difference in prognosis between exposed and unexposed cases. Among proximally exposed cases (<1·5 km from the hypocentre), chromosomal translocations and inversions were more frequent, and the frequency of structural alterations in chromosomes 3, 8, and 11 was significantly increased compared with unexposed cases. These results suggest that chromosomal alterations in MDS among survivors have different features compared with those in de novo or therapy-related MDS. Detailed molecular study is warranted.
[Mh] Termos MeSH primário: Aberrações Cromossômicas
Vítimas de Desastres
Síndromes Mielodisplásicas/epidemiologia
Síndromes Mielodisplásicas/genética
Armas Nucleares
Sobreviventes
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Contagem de Células Sanguíneas
Medula Óssea/patologia
Análise Citogenética
Feminino
Seres Humanos
Japão/epidemiologia
Masculino
Meia-Idade
Síndromes Mielodisplásicas/diagnóstico
Síndromes Mielodisplásicas/terapia
Avaliação de Resultados da Assistência ao Paciente
Sistema de Registros
Análise de Sobrevida
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180222
[Lr] Data última revisão:
180222
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171222
[St] Status:MEDLINE
[do] DOI:10.1111/bjh.15050


  5 / 57900 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29181840
[Au] Autor:Treon SP; Gustine J; Xu L; Manning RJ; Tsakmaklis N; Demos M; Meid K; Guerrera ML; Munshi M; Chan G; Chen J; Kofides A; Patterson CJ; Yang G; Liu X; Severns P; Dubeau T; Hunter ZR; Castillo JJ
[Ad] Endereço:Bing Center for Waldenstrom's Macroglobulinemia, Dana Farber Cancer Institute, Boston, MA, USA.
[Ti] Título:MYD88 wild-type Waldenstrom Macroglobulinaemia: differential diagnosis, risk of histological transformation, and overall survival.
[So] Source:Br J Haematol;180(3):374-380, 2018 02.
[Is] ISSN:1365-2141
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:MYD88 mutations are present in 95% of Waldenstrom Macroglobulinaemia (WM) patients, and support diagnostic discrimination from other IgM-secreting B-cell malignancies. Diagnostic discrimination can be difficult among suspected wild-type MYD88 (MYD88 ) WM cases. We systematically reviewed the clinical, pathological and laboratory studies for 64 suspected MYD88 WM patients. World Health Organization and WM consensus guidelines were used to establish clinicopathological diagnosis. Up to 30% of suspected MYD88 WM cases had an alternative clinicopathological diagnosis, including IgM multiple myeloma. The estimated 10-year survival was 73% (95% confidence interval [CI] 52-86%) for MYD88 versus 90% (95% CI 82-95%) for mutated (MYD88 ) WM patients (Log-rank P < 0·001). Multivariate analysis only showed MYD88 mutation status (P < 0·001) as a significant determinant for overall survival. Diffuse large B-cell lymphoma (DLBCL) was diagnosed in 7 (15·2%) and 2 (0·76%) of MYD88 and MYD88 patients, respectively (Odds ratio 23·3; 95% CI 4·2-233·8; P < 0·001). Overall survival was shorter among MYD88 patients with an associated DLBCL event (Log-rank P = 0·08). The findings show that among suspected MYD88 WM cases, an alternative clinicopathological diagnosis is common and can impact clinical care. WM patients with MYD88 disease have a high incidence of associated DLBCL events and significantly shorter survival versus those with MYD88 disease.
[Mh] Termos MeSH primário: Fator 88 de Diferenciação Mieloide/genética
Macroglobulinemia de Waldenstrom/diagnóstico
Macroglobulinemia de Waldenstrom/genética
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Biomarcadores
Medula Óssea/patologia
Transformação Celular Neoplásica
Análise Mutacional de DNA
Diagnóstico Diferencial
Feminino
Genótipo
Seres Humanos
Imunofenotipagem
Estimativa de Kaplan-Meier
Masculino
Meia-Idade
Mutação
Prognóstico
Modelos de Riscos Proporcionais
Macroglobulinemia de Waldenstrom/mortalidade
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Biomarkers); 0 (MYD88 protein, human); 0 (Myeloid Differentiation Factor 88)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180222
[Lr] Data última revisão:
180222
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171129
[St] Status:MEDLINE
[do] DOI:10.1111/bjh.15049


  6 / 57900 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29377069
[Au] Autor:Scharenberg C; Jansson M; Saft L; Hellström-Lindberg E
[Ad] Endereço:Department of Medicine, Centre for Haematology and Regenerative Medicine, Karolinska University Hospital Huddinge, Karolinska Institutet, Stockholm, Sweden.
[Ti] Título:Megakaryocytes harbour the del(5q) abnormality despite complete clinical and cytogenetic remission induced by lenalidomide treatment.
[So] Source:Br J Haematol;180(4):526-533, 2018 02.
[Is] ISSN:1365-2141
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:The mechanisms underlying lenalidomide-resistance of del(5q) MDS stem cells remain to be elucidated and may include cell-intrinsic as well as microenvironmental causes. Abnormal hypolobated megakaryocytes constitute one of the hallmarks of del(5q) MDS. We hypothesized that these cells have potential implications for the regulation of haematopoietic stem cells (HSC) similarly to what has recently been described for megakaryocytes in the murine system. Therefore, we conducted a study to determine the response of abnormal hypolobated megakaryocytes to lenalidomide therapy. We studied lenalidomide-treated patients in the MDS-004 trial as well as a cohort seen at our institution. Morphological evaluation at time of complete cytogenetic remission (CCyR) demonstrated the persistence of hypolobated megakaryocytes in all evaluable patients (n = 9). Furthermore, we provide evidence that the abnormal hypolobated morphology is restricted to del(5q) megakaryocytes, both at diagnosis and during CCyR. Using fluorescence in situ hybridisation analysis on flow-sorted stem- and progenitor populations, we observed a similar degree of clonal involvement in megakaryocyte-erythroid-progenitors as in HSC. Taken together, our findings suggest that megakaryocyte morphology might aid in the evaluation of patients where discontinuation of lenalidomide is considered and offers interesting hypotheses for further investigation of lenalidomide resistance.
[Mh] Termos MeSH primário: Antineoplásicos/uso terapêutico
Deleção Cromossômica
Cromossomos Humanos Par 5
Neoplasias Hematológicas/tratamento farmacológico
Neoplasias Hematológicas/genética
Megacariócitos/metabolismo
Talidomida/análogos & derivados
[Mh] Termos MeSH secundário: Antineoplásicos/administração & dosagem
Antineoplásicos/efeitos adversos
Medula Óssea/patologia
Evolução Clonal
Análise Citogenética
Neoplasias Hematológicas/diagnóstico
Seres Humanos
Imunofenotipagem
Hibridização in Situ Fluorescente
Células Progenitoras de Megacariócitos e Eritrócitos/metabolismo
Células Progenitoras de Megacariócitos e Eritrócitos/patologia
Megacariócitos/patologia
Indução de Remissão
Talidomida/administração & dosagem
Talidomida/efeitos adversos
Talidomida/uso terapêutico
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antineoplastic Agents); 4Z8R6ORS6L (Thalidomide); F0P408N6V4 (lenalidomide)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180221
[Lr] Data última revisão:
180221
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180130
[St] Status:MEDLINE
[do] DOI:10.1111/bjh.15094


  7 / 57900 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29390496
[Au] Autor:Lu K; Xu M; Li W; Wang K; Wang D
[Ad] Endereço:Department of Joint Surgery, Liaocheng Clinical College of Taishan Medical University.
[Ti] Título:A study on dynamic monitoring, components, and risk factors of embolism during total knee arthroplasty.
[So] Source:Medicine (Baltimore);96(51):e9303, 2017 Dec.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Fat embolism is a common complication of orthopedic surgery. However, the exact component and risk factor responsible for this complication remains unelucidated. This study aimed to detect the origin of the pulmonary embolus and identify relevant risk factors of pulmonary embolism in total knee replacement. METHODS: A total of 40 osteoarthritis patients who underwent primary unilateral TKA were recruited into this study. Transesophageal echocardiography (TEE) was utilized to dynamically monitor the embolism. Pulmonary arterial pressure was recorded and biopsies were obtained from the medullary cavity during surgery. RESULTS: After tourniquet release, the arterial embolism was observed by TEE to have a peak signal at 30 seconds when pulmonary arterial pressure was increased by 25% to 40% (P = .002). The pathology study of the embolism revealed its bone marrow origin. Total embolus quantity was positively correlated with age (P = .021), body mass index (BMI, P = .041), and fat content of the bone marrow (P = .003). Logistic regression analysis revealed that the fat content of the marrow (OR: 1.432, 95% CI: 1.335-1.592), age (OR: 1.632, 95% CI: 1.445-1.832), and BMI (OR: 1.231, 95% CI: 1.032-1.381) were risk factors for pulmonary hypertension. CONCLUSION: This study revealed that the embolus detected in the right atrium was derived from bone marrow tissues, and this led to pulmonary arterial pressure fluctuations after tourniquet release. Therefore, elderly patients who have high BMI or bone marrow fat content are at high-risk for pulmonary fat embolism during TKA.
[Mh] Termos MeSH primário: Artroplastia do Joelho/efeitos adversos
Embolia Gordurosa/diagnóstico por imagem
Átrios do Coração/diagnóstico por imagem
Monitorização Intraoperatória
[Mh] Termos MeSH secundário: Tecido Adiposo/patologia
Fatores Etários
Pressão Sanguínea
Índice de Massa Corporal
Medula Óssea/patologia
Ecocardiografia Transesofagiana
Embolia Gordurosa/etiologia
Feminino
Seres Humanos
Masculino
Meia-Idade
Osteoartrite do Joelho/cirurgia
Complicações Pós-Operatórias
Fatores de Risco
Torniquetes
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180220
[Lr] Data última revisão:
180220
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180203
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009303


  8 / 57900 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28470531
[Au] Autor:Vielreicher M; Friedrich O
[Ad] Endereço:Friedrich-Alexander University (FAU) Erlangen-Nürnberg, Institute of Medical Biotechnology, Paul-Gordan-Street 3, Erlangen, 91052, Germany. martin.vielreicher@mbt.uni-erlangen.de.
[Ti] Título:Assessment of Population and ECM Production Using Multiphoton Microscopy as an Indicator of Cell Viability.
[So] Source:Methods Mol Biol;1601:243-255, 2017.
[Is] ISSN:1940-6029
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Multiphoton microscopy allows continuous depth-resolved, nondestructive imaging of scaffold-seeded cells during cell or tissue culture. Spectrally separated images in high resolution can be provided while cells are conserved in their native state. Here we describe the seeding of mesenchymal stem cells to bacterial nanocellulose hydropolymer scaffolds followed by 2-channel imaging of cellular autofluorescence (AF) and collagen-I formation using second harmonic generation (SHG) signals. With this approach the simultaneous observation of the progression of cell morphology and production of extracellular matrix as hallmarks of viability and cell fitness is possible.
[Mh] Termos MeSH primário: Sobrevivência Celular
Matriz Extracelular/metabolismo
Células Mesenquimais Estromais/química
Microscopia de Fluorescência por Excitação Multifotônica
[Mh] Termos MeSH secundário: Animais
Medula Óssea/química
Células Cultivadas
Celulose/química
Colágeno Tipo I/biossíntese
Matriz Extracelular/ultraestrutura
Células Mesenquimais Estromais/citologia
Imagem Óptica
Ratos
Tecidos Suporte/química
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Collagen Type I); 9004-34-6 (Cellulose)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180219
[Lr] Data última revisão:
180219
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170505
[St] Status:MEDLINE
[do] DOI:10.1007/978-1-4939-6960-9_19


  9 / 57900 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29357857
[Au] Autor:Lee MY; Seo CS; Ha H; Park E; Kim JY; Shin HK
[Ad] Endereço:K-herb Research Center, Korea Institute of Oriental Medicine, 1672 Yuseongdae-ro, Yuseong-gu, Daejeon, 305-811, Republic of Korea.
[Ti] Título:The genotoxicity of an aqueous extract of Gyejibokryeong-hwan.
[So] Source:BMC Complement Altern Med;18(1):21, 2018 Jan 22.
[Is] ISSN:1472-6882
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Gyejibokryeong-hwan (Guizhi Fuling Wan in China), a mixture of five herbal plants, is a well-known treatment for renal diseases including those associated with climacteric syndrome. However, the genotoxicity of Gyejibokryeong-hwan has not yet been well established. METHODS: The present study investigated that the genotoxicity of an aqueous extract of Gyejibokryeong-hwan (GJBRHE): an in vitro chromosomal aberration test using Chinese hamster lung cells, an in vitro bacterial reverse mutation assay (Ames test) with Salmonella typhimurium and Escherichia coli strains, and an in vivo micronucleus test using ICR mouse bone marrow. RESULTS: GJBRHE with or without the S9 mix showed no genotoxicity in the Ames test up to 5000 µg/plate or in the in vivo MN test up to 2000 mg/kg body weight. In contrast, the chromosomal aberration test showed that GJBRHE induced an increase in the number of chromosomal aberrations compared with the control after treatment for 6 h with 4200 µg/mL GJBRHE in the presence of the S9 mix and for 22 h with 800 µg/mL GJBRHE in the absence of the S9 mix. CONCLUSIONS: GJBRHE did not cause detectable genotoxic effects in the bacterial mutation test or the in vivo MN test, however genotoxic effect was detected in the in vitro chromosomal aberration assay. Our results suggest that GJBRHE may be associated with a low risk of carcinogenesis. Thus, further detailed experiments would be needed to clarify the compound responsible for inducing this genotoxicity of GJBRHE and to determine its mechanism.
[Mh] Termos MeSH primário: Aberrações Cromossômicas/efeitos dos fármacos
Dano ao DNA/efeitos dos fármacos
Medicamentos de Ervas Chinesas/toxicidade
Mutagênicos/toxicidade
[Mh] Termos MeSH secundário: Animais
Peso Corporal/efeitos dos fármacos
Medula Óssea/efeitos dos fármacos
Linhagem Celular
Cricetinae
Escherichia coli/efeitos dos fármacos
Camundongos
Testes para Micronúcleos
Testes de Mutagenicidade
Salmonella typhimurium/efeitos dos fármacos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Drugs, Chinese Herbal); 0 (Mutagens); 0 (keishibukuryogan)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180216
[Lr] Data última revisão:
180216
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180124
[St] Status:MEDLINE
[do] DOI:10.1186/s12906-017-2054-z


  10 / 57900 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29346436
[Au] Autor:Egashira K; Sumita Y; Zhong W; I T; Ohba S; Nagai K; Asahina I
[Ad] Endereço:Department of Regenerative Oral Surgery, Unit of Translational Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
[Ti] Título:Bone marrow concentrate promotes bone regeneration with a suboptimal-dose of rhBMP-2.
[So] Source:PLoS One;13(1):e0191099, 2018.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Bone marrow concentrate (BMC), which is enriched in mononuclear cells (MNCs) and platelets, has recently attracted the attention of clinicians as a new optional means for bone engineering. We previously reported that the osteoinductive effect of bone morphogenetic protein-2 (BMP-2) could be enhanced synergistically by co-transplantation of peripheral blood (PB)-derived platelet-rich plasma (PRP). This study aims to investigate whether BMC can effectively promote bone formation induced by low-dose BMP-2, thereby reducing the undesirable side-effects of BMP-2, compared to PRP. Human BMC was obtained from bone marrow aspirates using an automated blood separator. The BMC was then seeded onto ß-TCP granules pre-adsorbed with a suboptimal-dose (minimum concentration to induce bone formation at 2 weeks in mice) of recombinant human (rh) BMP-2. These specimens were transplanted subcutaneously to the dorsal skin of immunodeficient-mice and the induction of ectopic bone formation was assessed 2 and 4 weeks post-transplantation. Transplantations of five other groups [PB, PRP, platelet-poor plasma (PPP), bone marrow aspirate (BM), and BM-PPP] were employed as experimental controls. Then, to clarify the effects on vertical bone augmentation, specimens from the six groups were transplanted for on-lay placement on the craniums of mice. The results indicated that BMC, which contained an approximately 2.5-fold increase in the number of MNCs compared to PRP, could accelerate ectopic bone formation until 2 weeks post-transplantation. On the cranium, the BMC group promoted bone augmentation with a suboptimal-dose of rhBMP-2 compared to other groups. Particularly in the BMC specimens harvested at 4 weeks, we observed newly formed bone surrounding the TCP granules at sites far from the calvarial bone. In conclusion, the addition of BMC could reduce the amount of rhBMP-2 by one-half via its synergistic effect on early-phase osteoinduction. We propose here that BMC transplantation facilitates the clinical use of rhBMP-2 as an alternative strategy for bone engineering.
[Mh] Termos MeSH primário: Medula Óssea
Proteína Morfogenética Óssea 2/farmacologia
Regeneração Óssea/efeitos dos fármacos
Fator de Crescimento Transformador beta/farmacologia
[Mh] Termos MeSH secundário: Animais
Relação Dose-Resposta a Droga
Feminino
Seres Humanos
Camundongos
Camundongos Endogâmicos BALB C
Proteínas Recombinantes/farmacologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Bone Morphogenetic Protein 2); 0 (Recombinant Proteins); 0 (Transforming Growth Factor beta); 0 (recombinant human bone morphogenetic protein-2)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180215
[Lr] Data última revisão:
180215
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180119
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0191099



página 1 de 5790 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde